The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis

Haematologica
Wataru NogamiYoshitaka Miyakawa

Abstract

Thrombocytopenia is a common problem in the management of patients with cancer and other conditions that affect hematopoietic cells. In previous clinical trials, the polyethylene-glycol-conjugated recombinant human megakaryocyte growth and development factor increased platelet counts in patients with idiopathic thrombocytopenic purpura and solid tumors undergoing chemotherapy. However, antibodies to polyethylene-glycol-conjugated recombinant human megakaryocyte growth and development factor develop in healthy volunteers and patients undergoing chemotherapy and cross-react with endogenous thrombopoietin. As a result, clinical development of polyethylene-glycol-conjugated recombinant human megakaryocyte growth and development factor was discontinued in 1998. The aim of this study was to identify an orally bioavailable human Mpl activator that does not develop autoantibodies against endogenous thrombopoietin. We screened our chemical library and created a novel non-peptidyl thrombopoietin receptor, Mpl activator named butyzamide. We evaluated the effect of butyzamide on megakaryopoiesis in vitro using Ba/F3 cells expressing Mpl and human hematopoietic stem cells. For the evaluation of its in vivo effect, we administered butyzamide...Continue Reading

Citations

Mar 16, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Erin E MatthewsDonald M Engelman
Jun 1, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Xiaoping GaoYanping Dai
Feb 17, 2011·Expert Review of Hematology·Abdulgabar Salama
May 21, 2013·Expert Opinion on Biological Therapy·Simon HallamAdrian C Newland
Oct 19, 2010·European Journal of Pharmacology·Masaki AbeHiroyuki Itoh
Nov 26, 2009·Hematology/oncology Clinics of North America·David J Kuter, Terry B Gernsheimer
Sep 26, 2009·Clinical Lymphoma & Myeloma·David J Kuter
Jul 28, 2009·Journal of Thrombosis and Haemostasis : JTH·Y Ikeda, Y Miyakawa
Aug 30, 2018·Journal of Cellular and Molecular Medicine·Chengying XieLiguang Lou
Jun 26, 2009·Current Opinion in Hematology·Adrian Newland
Mar 13, 2020·International Journal of Hematology·Masatoshi SakuraiSatoshi Yamazaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.